TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8314476
Drug: Interferon alfa‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa‐2b (12 months treatment)
Study: 25925674
Drug: Colchicine (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (standard daily dose)
Study: 22179917
Drug: 200 mcg
Normalized name: CrM 200 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mcg Misoprostol sublingually, 2 hours before diagnostic hysteroscopy
Study: 22179917
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no prior preparation)
Study: 22179917
Drug: 200 mcg
Normalized name: CrM 200 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mcg Misoprostol sublingually, 2 hours before diagnostic hysteroscopy (in postmenopausal women)
Study: 22179917
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no prior preparation, in postmenopausal women)
Study: 22179917
Drug: 200 mcg
Normalized name: CrM 200 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mcg Misoprostol sublingually, 2 hours before diagnostic hysteroscopy (in patients with a history of vaginal delivery)
Study: 22179917
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no prior preparation, in patients with a history of vaginal delivery)
Study: 12858920
Drug: Rectal dihydroartemisinin
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal dihydroartemisinin (DATM)
Study: 8807058
Drug: ZDV plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZDV plus didanosine plus escalating doses (400 to 1,200 mg/day) of delavirdine (DLV) (group 2)
Study: 8807058
Drug: 1,200 mg
Normalized name: lecithin 1,200 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,200 mg of DLV alone per day (group 3)
Study: 8807058
Drug: ZDV plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZDV plus 1,200 mg of DLV per day (group 4)
Study: 6393814
Drug: Pirenzepine and
Normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine and antacids
Study: 25210016
Drug: Ipilimumab retreatment
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab retreatment at 10 mg/kg
Study: 25210016
Drug: Ipilimumab induction
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab induction at 0.3 mg/kg
Study: 25210016
Drug: Ipilimumab induction
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab induction at 3 mg/kg
Study: 25210016
Drug: Ipilimumab induction
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab induction at 10 mg/kg
Study: 25210016
Drug: Ipilimumab induction
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab induction at 3 mg/kg (treatment-naive)
Study: 25210016
Drug: Ipilimumab induction
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab induction at 10 mg/kg (treatment-naive)
Study: 25210016
Drug: Ipilimumab retreatment
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab retreatment (0.3 mg/kg)
Study: 25210016
Drug: Ipilimumab retreatment
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab retreatment (3 mg/kg)
Study: 25210016
Drug: Ipilimumab retreatment
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab retreatment (10 mg/kg)
Study: 17229252
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (other disease-modifying anti-rheumatic drug therapies)
Study: 27889574
Drug: Budesonide Oral
Normalized name: budesonide Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide Oral Suspension (BOS) 2 mg twice daily for 12 weeks
Study: 10764435
Drug: NAC (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAC (cisplatin 50 mg/m², vincristine 1 mg/m² for 1 day, bleomycin 25 mg/m² for 3 days for three cycles followed by radical hysterectomy
Study: 1444609
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (40 mg weekly for 8 weeks, with two additional instillations every 15 days in 50 ml saline)
Study: 1444609
Drug: Mitoxantrone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone (20 mg weekly for 8 weeks, with two additional instillations every 15 days in 50 ml saline)
Study: 2932307
Drug: Cleocin T
Normalized name: Cleocin T
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cleocin T Topical 1 percent Solution
Study: 2932307
Drug: Cleocin T
Normalized name: Cleocin T
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cleocin T Topical 1 percent Lotion
Study: 28663395
Drug: Femoral nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femoral nerve block with 75 mg of 0.25% levobupivacaine hydrochloride
Study: 28663395
Drug: Periarticular infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periarticular infiltration with 150 mg of 0.25% levobupivacaine hydrochloride, 10 mg morphine sulphate, 30 mg ketorolac trometamol, 0.25 mg of adrenaline diluted with 0.9% saline to 150 ml
Study: 23474642
Drug: tele‐SEGT (supportive‐expressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: tele‐SEGT (supportive‐expressive group therapy)
Study: 19725253
Drug: Diclofenac potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac potassium (150 mg per day)
Study: 17964975
Drug: Ibuprofen (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (7 mg/kg every 8 h)
Study: 15094573
Drug: IV ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ketamine 1 mg/kg
Study: 15094573
Drug: IV midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV midazolam 0.15 mg/kg
Study: 15094573
Drug: IV ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ketamine 1 mg/kg plus IV midazolam 0.1 mg/kg
Study: 15094573
Drug: IV midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV midazolam 0.1 mg/kg plus IV fentanyl 2 microg/kg
Study: 15094573
Drug: IV propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV propofol 2 mg/kg
Study: 11820726
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of bovine pancreatic chymotrypsin
Study: 11820726
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of papain
Study: 11820726
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of bacterial protease from Bacillus licheniformis
Study: 11820726
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of Alcalase
Study: 11820726
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of Optimase
Study: 11820726
Drug: Occluded application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occluded application of aqueous enzyme solution
Study: 11820726
Drug: Two-step unoccluded
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two-step unoccluded application of aqueous enzyme solution followed by commercial moisturizer
Study: 9428539
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (TPN group; n = 56)
Study: 4758487
Drug: Low nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low nicotine cigarettes (<0.3 mg)
Study: 4758487
Drug: High nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High nicotine cigarettes (3.2 mg)
Study: 25847690
Drug: DM-1992 (extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: DM-1992 (extended-release carbidopa/levodopa), 2 times per day
Study: 25847690
Drug: CD/L-dopa IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD/L-dopa IR (immediate-release carbidopa/levodopa), 4.8 times per day
Study: 25847690
Drug: CD/L-dopa IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD/L-dopa IR
Study: 19654956
Drug: Oral uridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral uridine
Study: 16740612
Drug: Systemic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic administration of intravenous terbutaline (TRB)
Study: 16740612
Drug: Forearm blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forearm blood flow (FBF) response to incremental doses of isoprenaline
Study: 11227395
Drug: Olanzapine 10
Normalized name: olanzapine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 10 to 20 mg/day
Study: 11227395
Drug: Risperidone 4
Normalized name: risperidone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 4 to 12 mg/day
Study: 9024451
Drug: Prednisone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (4 mg/kg per day)
Study: 8420726
Drug: Cimetidine (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (n = 65) as an iv infusion of 50 to 100 mg/hr
Study: 6981177
Drug: Trimethoprim-sulfamethoxazole (TMP-SMZ)
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMZ) intravenously for at least four days or orally for at least nine days (total daily dose, 10-20 mg/kg)
Study: 6981177
Drug: Trimethoprim-sulfamethoxazole (TMP-SMZ)
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMZ) therapy
Study: 6981177
Drug: Initial intravenous
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial intravenous therapy with doses of 15-20 mg/kg per day
Study: 28109298
Drug: Intravenous G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous G-CSF followed by mPBMC infusion
Study: 28109298
Drug: Intravenous G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous G-CSF followed by mPBMC infusion at 7 months (T7 group)
Study: 28109298
Drug: Intravenous G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous G-CSF followed by mPBMC infusion at 1 month (T1 group)
Study: 28109298
Drug: mPBMC infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mPBMC infusion
Study: 24554302
Drug: Prulifloxacin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prulifloxacin (600 mg once a week for 12 weeks)
Study: 24554302
Drug: Fosfomycin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosfomycin (3 g once a week for 12 weeks)
Study: 21636230
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with clarithromycin (200mg/day) and S-carboxymethylcysteine (1500mg/day) for 12 weeks
Study: 21636230
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with clarithromycin (200mg/day) for 12 weeks
Study: 21636230
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with clarithromycin and S-carboxymethylcysteine
Study: 21636230
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (combination and monotherapy)
Study: 19489132
Drug: 200 mcg
Normalized name: CrM 200 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mcg HFA-BDP bid for 12 weeks
Study: 19489132
Drug: 400 mcg
Normalized name: Biotin 400 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mcg CFC-BDP bid for 12 weeks
Study: 17407649
Drug: DPP-4 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DPP-4 inhibitors as monotherapy
Study: 17407649
Drug: DPP-4 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DPP-4 inhibitors as add-on therapy
Study: 12780372
Drug: NRT (nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRT (nicotine replacement therapy)
Study: 8936558
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of vitamin E per day
Study: 8936558
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of vitamin C per day
Study: 6193665
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of dextran 1, 15% administered intravenously two minutes before infusion of dextran 70 or dextran 40
Study: 6193665
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of dextran 1, 15%
Study: 28421567
Drug: Oral treatment
Normalized name: Other agents for local oral treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral treatment (28 tablets of 1000 µg cyanocobalamin per month)
Study: 28421567
Drug: Intramuscular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular treatment (four weekly injections of 1000 µg hydroxocobalamin)
Study: 28421567
Drug: Intramuscular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular treatment
Study: 21882997
Drug: Internet-based behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based behavioral weight loss program with weekly group meetings delivered entirely by online synchronous chats
Study: 21882997
Drug: Internet-based behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based behavioral weight loss program with weekly group meetings delivered by a combination of online chats plus monthly in-person group sessions
Study: 17022844
Drug: Ropinirole 0.25‐4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole 0.25‐4.0 mg once daily 1‐3 hours before bedtime
Study: 9114180
Drug: Sequential episodes
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential episodes of C. difficile diarrhea
Study: 1549227
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin (average doses: 5 to 10, 10 to 20, and 20 to 40 units per muscle)
Study: 31179007
Drug: 3-day placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day placebo treatment
Study: 22508360
Drug: 25% (w/v)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% (w/v) honey solution
Study: 18005909
Drug: EPs (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPs (30 drops, 1.5 mL, three times a day for a maximum of 10 days)
Study: 9563220
Drug: metronidazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: metronidazole (400 mg t.i.d. for 7 days)
Study: 9563220
Drug: secnidazole (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: secnidazole (500 mg t.i.d. for 5 days)
Study: 7996065
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose steroids
Study: 29778364
Drug: Cilostazol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol (100 mg twice a day)
Study: 29778364
Drug: Cilostazol plus
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol plus probucol (250 mg twice a day)
Study: 29778364
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus probucol
Study: 28142074
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (OT) treatment on scan 2
Study: 28142074
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (OT) treatment
Study: 26226536
Drug: Proactive QL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive QL intervention with up to an 8-week supply of free nicotine replacement therapy
Study: 26226536
Drug: Reactive QL
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reactive QL intervention with a 2-week supply of nicotine replacement therapy
Study: 17044457
Drug: Tacrolimus +
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus + Fluconazole (100-200 mg/day for one week)
Study: 17044457
Drug: Tacrolimus (stable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus (stable dosage)
Study: 8638341
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg twice daily for seven days postoperatively
Study: 8638341
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no NSAID treatment)
Study: 6223651
Drug: Nebulized salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized salbutamol solution
Study: 25057105
Drug: 5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g/day of Arthrospira platensis (Asp)
Study: 23083772
Drug: AMG 145
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 145 (doses of 7, 21, 70, 210, or 420 mg SC; 21 or 420 mg IV; 14 or 35 mg QW ×6; 140 or 280 mg Q2W ×3; 420 mg every 4 weeks ×2)
Study: 23083772
Drug: AMG 145
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 145 (140 mg Q2W ×3)
Study: 20179322
Drug: C.E.R.A. administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: C.E.R.A. administered via intravenous (IV) route once every 2 weeks (Q2W)
Study: 20179322
Drug: C.E.R.A. administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: C.E.R.A. administered via subcutaneous (SC) route once every 4 weeks (Q4W)
Study: 20179322
Drug: C.E.R.A. administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: C.E.R.A. administration (IV or SC)
Study: 20179322
Drug: Dosing schedule,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing schedule, administration route, and study type
Study: 18990320
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of DHEA daily for 12 weeks
Study: 15931623
Drug: Intravenous cyanocobalamin
Normalized name: Cyanocobalamin
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cyanocobalamin every 14 days
Study: 15931623
Drug: Intravenous cyanocobalamin
Normalized name: Cyanocobalamin
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cyanocobalamin every 7 days
Study: 15931623
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (1 mg intravenous cyanocobalamin every 28 days)
Study: 12939214
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of a prothrombotic risk factor with an underlying condition
Study: 9179835
Drug: Decision support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decision support using the hand-held patient-oriented insulin regimen optimizer (POIRO)
Study: 6367528
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (AMCA) 1 g t.i.d. 24 h prior to and following intradermal injection of anti-IgE
Study: 23010094
Drug: 17 alpha-hydroxyprogesterone
Normalized name: 17 alpha-hydroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 alpha-hydroxyprogesterone caproate (250 mg, weekly intramuscular)
Study: 18707726
Drug: Cranberry juice
Normalized name: cranberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry juice cocktail (3 times daily)
Study: 18707726
Drug: Cranberry juice
Normalized name: cranberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry juice (multiple daily dosing)
Study: 10573193
Drug: Clomipramine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine at 0.5 to 1.0 mg/kg twice daily
Study: 10573193
Drug: Clomipramine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine at 1.0 to 2.0 mg/kg twice daily
Study: 8916636
Drug: Participants whose
Normalized name: Allium fistulosum whoe extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants whose depression symptoms decreased from baseline to the end of treatment
Study: 8916636
Drug: Participants whose
Normalized name: Allium fistulosum whoe extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants whose depression symptoms increased from baseline to the end of treatment
Study: 6218577
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard antimicrobial therapy)
Study: 31806944
Drug: Radial extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial extracorporeal shock wave therapy (rESWT) with 2000 pulses; 2.5 bars; 5 Hz, 7 mins, performed twice a week for five weeks (10 sessions) and stabilization training
Study: 31806944
Drug: Radial extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial extracorporeal shock wave therapy (rESWT) with stabilization training
Study: 19632665
Drug: 10 units
Normalized name: Omnipod GO 10 Units/Day Pods
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 units of intramuscular oxytocin (group 1)